[A Case of m0CRPC after Hormone Therapy for Pelvic Lymph Node Metastasis in which Salvage RARP was Effective].

Q4 Medicine

Acta Urologica Japonica Pub Date : 2023-02-01 DOI:10.14989/ActaUrolJap_69_2_59

Hidetoshi Kokubun, Masashi Kubota, Takanari Kambe, Yuta Mine, Hiroki Hagimoto, Ritsuki Yamaguchi, Shiori Murata, Noriyuki Makita, Yuto Hattori, Yohei Abe, Naofumi Tsutsumi, Toshinari Yamasaki, Koji Inoue, Mutsushi Kawakita

{"title":"[A Case of m0CRPC after Hormone Therapy for Pelvic Lymph Node Metastasis in which Salvage RARP was Effective].","authors":"Hidetoshi Kokubun, Masashi Kubota, Takanari Kambe, Yuta Mine, Hiroki Hagimoto, Ritsuki Yamaguchi, Shiori Murata, Noriyuki Makita, Yuto Hattori, Yohei Abe, Naofumi Tsutsumi, Toshinari Yamasaki, Koji Inoue, Mutsushi Kawakita","doi":"10.14989/ActaUrolJap_69_2_59","DOIUrl":null,"url":null,"abstract":"<p><p>The patient was a 63-year-old man with biopsy Gleason score of 4＋5 prostate cancer with an initial prostate specific antigen level of (PSA) 51.2ng/ml. On imaging examination, extracapsular invasion, rectal invasion, and pararectal lymph node metastasis were found (cT4N1M0). After 4 years of androgen deprivation therapy, PSA decreased to 0.631ng/ml, and then increased gradually to1.2ng/ml. Computed tomographic scan showed that the primary tumor had shrunk and lymph node metastasis had disappeared; so salvage robot-assisted resection of the prostate (RARP) was performed for non-metastatic castration-resistant prostate cancer (m0CRPC). Since PSA decreased to an undetactable level, hormone therapy was terminated at 1 year. The patient remained recurrence-free for 3 years after surgery. RARP may be effective for m0CRPC, enabling discontinuation of androgen deprivation therapy.</p>","PeriodicalId":39291,"journal":{"name":"Acta Urologica Japonica","volume":"69 2","pages":"59-62"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Urologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14989/ActaUrolJap_69_2_59","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The patient was a 63-year-old man with biopsy Gleason score of 4＋5 prostate cancer with an initial prostate specific antigen level of (PSA) 51.2ng/ml. On imaging examination, extracapsular invasion, rectal invasion, and pararectal lymph node metastasis were found (cT4N1M0). After 4 years of androgen deprivation therapy, PSA decreased to 0.631ng/ml, and then increased gradually to1.2ng/ml. Computed tomographic scan showed that the primary tumor had shrunk and lymph node metastasis had disappeared; so salvage robot-assisted resection of the prostate (RARP) was performed for non-metastatic castration-resistant prostate cancer (m0CRPC). Since PSA decreased to an undetactable level, hormone therapy was terminated at 1 year. The patient remained recurrence-free for 3 years after surgery. RARP may be effective for m0CRPC, enabling discontinuation of androgen deprivation therapy.

查看原文本刊更多论文

[1例盆腔淋巴结转移激素治疗后m0CRPC，挽救性RARP有效]。

患者为63岁男性，活检Gleason评分为4+5前列腺癌，初始前列腺特异性抗原(PSA) 51.2ng/ml。影像学检查发现囊外浸润、直肠浸润、直肠旁淋巴结转移(cT4N1M0)。雄激素剥夺治疗4年后，PSA降至0.631ng/ml，后逐渐升高至1.2ng/ml。计算机断层扫描显示原发肿瘤缩小，淋巴结转移消失;因此，对于非转移性去势抵抗性前列腺癌(m0CRPC)，采用机器人辅助前列腺切除术(RARP)。由于PSA下降到不可分离的水平，激素治疗在1年终止。患者术后3年无复发。RARP可能对m0CRPC有效，可以停止雄激素剥夺治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Urologica Japonica Medicine-Medicine (all)

CiteScore

0.20

自引率

0.00%

发文量